MarketCap
Celldex Therapeutics CLDX
$ 31.12
0.28%
Facebook
X
Telegram
Celldex Therapeutics Cash and Cash Equivalents | CLDX
Annual Cash and Cash Equivalents Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.9 M | 28.4 M | 34.8 M | 29.4 M | 39.1 M | 43.8 M | 11.2 M | 24.3 M | 40.3 M | 42.5 M | 72.1 M | 28 M | 169 M | 24.9 M | 11.9 M | 21.3 M | 57 M | 44.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 169 M | 11.2 M | 41.8 M |
Quarterly Cash and Cash Equivalents Celldex Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.5 M | 35.7 M | 36 M | 23 M | 17.1 M | 28.4 M | 36.4 M | 42.7 M | 115 M | 34.8 M | 21.1 M | 28.2 M | 54.1 M | 29.4 M | 18.6 M | 28.4 M | 25.3 M | 39.1 M | 72.2 M | 43.4 M | 69.3 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 24.3 M | 24.3 M | 24.3 M | 24.3 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 72.1 M | 72.1 M | 72.1 M | 72.1 M | 28 M | 28 M | 28 M | 28 M | 169 M | 169 M | 169 M | 169 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 169 M | 11.2 M | 44.6 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
261 M | $ 1.31 | 6.5 % | $ 166 M |  Schweiz |
 |
ADMA Biologics
ADMA
|
87.6 M | $ 9.7 | 3.21 % | $ 2.31 B |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
70.5 M | $ 27.89 | 0.3 % | $ 4.23 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 13.3 | 1.06 % | $ 364 M |  Israel |
 |
AbbVie
ABBV
|
5.23 B | $ 265.08 | 0.02 % | $ 469 B | USA |
 |
Axsome Therapeutics
AXSM
|
323 M | $ 193.45 | 0.24 % | $ 9.62 B | USA |
 |
Aytu BioScience
AYTU
|
26.3 M | $ 2.28 | 2.24 % | $ 28.1 M | USA |
 |
Adagene
ADAG
|
74.5 M | $ 2.97 | 0.62 % | $ 175 M |  China |
 |
Abeona Therapeutics
ABEO
|
78.4 M | $ 5.53 | 2.65 % | $ 293 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
5.88 M | $ 4.04 | 0.24 % | $ 2.7 M | USA |
 |
Evelo Biosciences
EVLO
|
47.9 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.31 B | $ 62.21 | 0.06 % | $ 11.9 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.85 | 0.2 % | $ 929 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.53 M | $ 2.16 | 0.45 % | $ 3.56 M | Israel |
 |
Achieve Life Sciences
ACHV
|
20.9 M | $ 7.83 | 0.87 % | $ 341 M | USA |
 |
Catalyst Biosciences
CBIO
|
37.1 M | $ 14.19 | 1.17 % | $ 1.27 B | USA |
 |
Amryt Pharma plc
AMYT
|
113 M | - | - | $ 621 M |  Britain |
 |
C4 Therapeutics
CCCC
|
74.6 M | $ 3.08 | 0.3 % | $ 255 M | USA |
 |
Codexis
CDXS
|
50.8 M | $ 1.38 | 0.72 % | $ 120 M | USA |
 |
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | USA |
 |
Cerus Corporation
CERS
|
20 M | $ 2.6 | 4.3 % | $ 496 M | USA |
 |
Coherus BioSciences
CHRS
|
88.9 M | $ 1.26 | 1.48 % | $ 148 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
5.59 M | $ 4.04 | 4.94 % | $ 49.3 M | Israel |
 |
AbCellera Biologics
ABCL
|
129 M | $ 12.31 | 0.12 % | $ 3.68 B | Canada |
 |
Aclaris Therapeutics
ACRS
|
20 M | $ 5.26 | 2.69 % | $ 645 M | USA |
 |
Clovis Oncology
CLVS
|
143 M | - | -7.23 % | $ 13 M | USA |
 |
Cocrystal Pharma
COCP
|
7.02 M | $ 1.19 | 1.26 % | $ 13.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
231 M | $ 22.45 | 1.05 % | $ 711 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
120 M | $ 112.94 | 3.29 % | $ 11.7 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
102 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
28.5 M | $ 7.74 | 0.19 % | $ 103 M | USA |
 |
Cardiff Oncology
CRDF
|
17.5 M | $ 1.31 | 0.74 % | $ 87.6 M | USA |
 |
Curis
CRIS
|
5.06 M | $ 0.95 | 0.98 % | $ 12.5 M | USA |
 |
CorMedix
CRMD
|
145 M | $ 7.69 | 0.06 % | $ 554 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
348 M | $ 55.76 | 1.2 % | $ 5.01 B | Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
4.58 M | $ 12.54 | 8.21 % | $ 990 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
142 M | - | - | $ 401 M | USA |
 |
Cue Biopharma
CUE
|
27.1 M | $ 31.71 | 2.62 % | $ 3 B | USA |
 |
CEL-SCI Corporation
CVM
|
11 M | $ 1.68 | 0.59 % | $ 13.5 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
123 M | $ 65.81 | 0.04 % | $ 7.9 M | USA |
 |
Axon Enterprise
AXON
|
1.2 B | $ 450.61 | 1.61 % | $ 35.2 B | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
15.6 M | $ 7.56 | 7.16 % | $ 355 M | USA |
 |
Denali Therapeutics
DNLI
|
205 M | $ 20.46 | 5.52 % | $ 3.53 B | USA |
 |
Precision BioSciences
DTIL
|
111 M | $ 6.36 | 10.62 % | $ 81.6 M | USA |
 |
Dyadic International
DYAI
|
4.62 M | $ 0.41 | 3.72 % | $ 14.8 M | USA |
 |
Editas Medicine
EDIT
|
147 M | $ 2.69 | 0.17 % | $ 239 M | USA |
 |
Edesa Biotech
EDSA
|
10.8 M | $ 3.97 | 1.46 % | $ 22.5 M | USA |